Transdermal contraceptive formulations methods and devices
US5512292A · kind A · utility
20Cited by
25References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 21, 1994 |
| Grant date | Apr 30, 1996 |
| Priority date | — |
| Expiry date | Dec 21, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compositions and methods for the transdermal administration of a contraceptively effective amount of gestodene and estrogen, such as ethinyl estradiol, in combination, together with a suitable permeation enhancer. The amount of the estrogen codelivered is kept at an about constant and contraceptively effective rate while the amount of gestogen codelivered varies depending on the phase of the menstrual cycle but remains at a contraceptively effective rate. The size of the system may also vary depending on the amount of gestogeno be delivered.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.